Quick Answer
Damora Therapeutics, Inc. reported Total Assets of $260.53 million for the year ending 2025.
- Damora Therapeutics, Inc. showed an increase of +1,420.7% in Total Assets from 2024 to 2025.
- This data is from Damora Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $98.15 million | Q1 2021: $158.66 million | Q2 2021: $146.82 million | Q3 2021: $135.87 million | Q1 2022: $108.93 million | Q2 2022: $92.86 million | Q3 2022: $82.03 million | Q1 2023: $64.63 million | Q2 2023: $58.80 million | Q3 2023: $50.05 million | Q1 2024: $32.48 million | Q2 2024: $27.30 million | Q3 2024: $23.38 million | Q1 2025: $15.37 million | Q2 2025: $13.69 million | Q3 2025: $10.74 million.
- Over the full 7 years of available data (2019 to 2025), Damora Therapeutics, Inc.'s Total Assets has grown by 360.2%.
- Historical annual values: Fiscal year 2025: $260.53 million | Fiscal year 2024: $17.13 million | Fiscal year 2023: $38.23 million | Fiscal year 2022: $73.19 million | Fiscal year 2021: $122.22 million | Fiscal year 2020: $171.60 million | Fiscal year 2019: $56.61 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: